Lorena Lopez
Psychiatric/Mental Health · Kissimmee, FLNPI 1629632898
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 313 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Johnson & Johnson at 27.7% of the total. 2025 is the largest year on record at $1,929, 4.0 times the $480 reported in 2021. Among psychiatric/mental health clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 313 payments — averaging $19.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$831
- Alkermes, Inc.$695
- Neurocrine Biosciences, Inc.$264
- Vanda Pharmaceuticals Inc.$239
- plus $1K from 20 others
What the payments were for
- Food & beverage$6,08599%
- Education$781%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 81 | $1,705 |
| AbbVie | 61 | $1,136 |
| Otsuka America Pharmaceutical, Inc. | 47 | $831 |
| Alkermes, Inc. | 39 | $695 |
| Neurocrine Biosciences, Inc. | 14 | $264 |
| Vanda Pharmaceuticals Inc. | 9 | $239 |
| Axsome Therapeutics, Inc. | 8 | $223 |
| Corium, LLC | 14 | $215 |
| Calliditas Therapeutics US Inc. | 2 | $139 |
| Vifor Pharma, Inc. | 5 | $110 |
| AstraZeneca(2 entities) | 6 | $102 |
| Bayer | 3 | $68 |
| Sunovion Pharmaceuticals Inc. | 4 | $62 |
| Vantive US Healthcare LLC | 2 | $56 |
| Noven Therapeutics, LLC | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $48 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $37 |
| Lundbeck LLC | 2 | $32 |
| Aurinia Pharma U.S., Inc. | 1 | $27 |
| Baxter Healthcare | 1 | $24 |
| OPKO Pharmaceuticals, LLC | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Novo Nordisk | 1 | $16 |
| Merck | 1 | $12 |
| Genentech USA, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,163 in reported general payments places this provider in the 90th percentile of 3,096 psychiatric/mental health providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bupropion XlBupropion Hcl | 18 | $968 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 15 | $829 |
| Allopurinol | 31 | $430 |
| Quetiapine Fumarate | 17 | $215 |
| Olanzapine | 11 | $192 |
| Hydroxyzine Pamoate | 17 | $124 |
| Trazodone Hcl | 17 | $111 |
| Sertraline Hcl | 32 | $88 |
| Alprazolam | 26 | $73 |
| Escitalopram Oxalate | 11 | $34 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Kissimmee
- Roger RiveraKissimmee$1.6M
- Trinese HardyKissimmee$30K
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Scott DurrancePensacola$224K
- Eudaldo AponteHialeah$214K
- Heather WarrenTallahassee$172K
- Angela DavenportAlachua$83K
- Natalie MoodyWinter Haven$75K
- Kelli BridgmanNew Smyrna Beach$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.